ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis

S. Munoz,1 D. Reich,2 K. Rothstein.1

1Div of Hepatology, Liver Failure Unit, Hanemann University Hospital, Philadelphia, PA
2Liver, Kidney and Pancreas Transplant Program, Hahnemann University Hospital, Philadelphia, PA.

Meeting: 2015 American Transplant Congress

Abstract number: 223

Keywords: Allocation, Hepatitis, Hepatitis C, Liver transplantation

Session Information

Session Name: Concurrent Session: Liver Transplantation: Viral Hepatitis

Session Type: Concurrent Session

Date: Monday, May 4, 2015

Session Time: 2:15pm-3:45pm

 Presentation Time: 2:51pm-3:03pm

Location: Terrace IV

The approval of potent antiviral therapy (AVT) with sofosfuvir/ledipasvir (sof/ldv) for hepatitis C (HCV) dramatically increased cure rates (SVR) to nearly 100%. A recent prospective trial in decomp. cirrhosis (Child B/C) reported an 89-91% cure and a mean MELD reduction of 2.5 points) after AVT with sof/ldv/rib (Flamm, Hepatology 2014;(60):320A, AASLD 2014). Aim: to evaluate consequences of ATV-induced MELD reduction on transplant wait-listed patients' continued need for liver allocation. Methods: Characteristics and MELD scores of HCV patients listed for liver transplantation (LTx) in 2012 (SRTR, n=4,612) were used as the study database. To evaluate AVT-MELD interactions, the observed reduction MELD score of 2.5 points by12 weeks of sof/ldv/rib in decomp. cirrhotics was incorporated into 3 models: A, MELD returned to pre-AVT level after completion of AVT; B: MELD improved by 2.5 points by end of AVT and remained stable thereafter; C: MELD continued to improve by 2.5 points every 3 months as a result of HCV cure by ATV. Primary outcome was "time to improve to a MELD of 15" (TTI-15; the threshold for LTx benefit). Model assumptions included: listed pts. treatment rate: 80%, cure (SVR) rate: 90% (as reported above), all patients conformed to the same model, and none deteriorated during AVT or after SVR. Natural MELD was assessed without upgrades for HCC. Results: In the A and B models there was no effect on primary outcome (TTI-15). C: listed patients with MELD > 35 reached TTI-15) in 34.5 months (30-39); those listed with MELD 25-35 reached TTI-15 in 27 mo (24-30), and those listed with MELD 15-25 reached TTI-15 in 12 mo (9-15). Estimates from the C model applied to the 2012 national LTx waiting list suggest that ATV-induced MELD reduction down to the threshold of 15 points would occur in 2,820 HCV patients (61.1% of all listed HCV-patients) over a period of 13.2 months (range:9-39) from the start of ATV. Simultaneously, approximately 857 donated livers would become available for re-distribution to other listed patients, leading to a substantial decrease in the gap between listed patients and available livers.

Conclusions: The high cure rates achieved with the new potent and safe HCV AVT in decompensated Childs class B and C cirrhotics are likely to have a substantial impact on the liver transplant wait-list and organ allocation.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Munoz S, Reich D, Rothstein K. The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/the-impact-of-the-new-antivirals-sofosfuvirledipasvir-on-liver-transplantation-for-hepatitis-c-cirrhosis/. Accessed June 1, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences